Tethering Innate Surface Receptors on Dendritic Cells: A New Avenue for Immune Tolerance Induction?

• Published in: International journal of molecular sciences Vol. 21; no. 15
• Main Authors: Lamendour, Lucille, Deluce-Kakwata-Nkor, Nora, Mouline, Caroline, Gouilleux-Gruart, Valérie, Velge-Roussel, Florence
• Format: Journal Article
• Language: English
• Published: MDPI 24-07-2020
• Subjects: Life Sciences
• ISSN: 1661-6596; 1422-0067
• DOI: 10.3390/ijms21155259

Dendritic cells (DCs) play a key role in immunity and are highly potent at presenting antigens and orienting the immune response. Depending on the environmental signals, DCs could turn the immune response toward immunity or immune tolerance. Several subsets of DCs have been described, with each expressing various surface receptors and all participating in DC-associated immune functions according to their specific skills. DC subsets could also contribute to the vicious circle of inflammation in immune diseases and establishment of immune tolerance in cancer. They appear to be appropriate targets in the control of inflammatory diseases or regulation of autoimmune responses. For all these reasons, in situ DC targeting with therapeutic antibodies seems to be a suitable way of modulating the entire immune system. At present, the field of antibody-based therapies has mainly been developed in oncology, but it is undergoing remarkable expansion thanks to a wide variety of antibody formats and their related functions. Moreover, current knowledge of DC biology may open new avenues for targeting and modulating the different DC subsets. Based on an update of pathogen recognition receptor expression profiles in human DC subsets, this review evaluates the possibility of inducing tolerant DCs using antibody-based therapeutic agents.